Last $6.37 USD
Change Today -0.05 / -0.78%
Volume 626.0K
ACRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 4:00 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

acelrx pharmaceuticals inc (ACRX) Snapshot

Open
$6.46
Previous Close
$6.42
Day High
$6.57
Day Low
$6.34
52 Week High
03/6/14 - $13.64
52 Week Low
10/31/13 - $6.04
Market Cap
276.3M
Average Volume 10 Days
701.4K
EPS TTM
$-0.29
Shares Outstanding
43.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACELRX PHARMACEUTICALS INC (ACRX)

acelrx pharmaceuticals inc (ACRX) Related Bloomberg News

View More Bloomberg News

acelrx pharmaceuticals inc (ACRX) Related Businessweek News

No Related Businessweek News Found

acelrx pharmaceuticals inc (ACRX) Details

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP); and ARX-03, a Sufentanil/Triazolam NanoTab, a Phase II clinical trials completed product designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

44 Employees
Last Reported Date: 08/11/14
Founded in 2005

acelrx pharmaceuticals inc (ACRX) Top Compensated Officers

Chief Executive Officer, President, Chief Com...
Total Annual Compensation: $475.0K
Co-Founder, Chief Medical Officer and Directo...
Total Annual Compensation: $409.0K
Chief Engineering Officer
Total Annual Compensation: $301.0K
Chief Development Officer
Total Annual Compensation: $292.8K
Compensation as of Fiscal Year 2013.

acelrx pharmaceuticals inc (ACRX) Key Developments

AcelRx Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

AcelRx Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $71,000 against $407,000 a year ago. Loss from operations was $12,260,000 against $7,771,000 a year ago. Net loss was $10,575,000 or $0.30 per diluted share against $17,447,000 or $0.47 per basic and diluted share a year ago. For the six months, the company reported total revenue of $166,000 against $1,347,000 a year ago. Loss from operations was $20,801,000 against $18,340,000 a year ago. Net loss was $20,206,000 or $0.50 per diluted share against $30,209,000 or $0.81 per basic and diluted share a year ago.

AcelRx Pharmaceuticals, Inc. to Report Q2, 2014 Results on Aug 11, 2014

AcelRx Pharmaceuticals, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 11, 2014

AcelRx Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 11, 2014

AcelRx Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACRX:US $6.37 USD -0.05

ACRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACRX.
View Industry Companies
 

Industry Analysis

ACRX

Industry Average

Valuation ACRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.8x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACELRX PHARMACEUTICALS INC, please visit www.acelrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.